Introducing Nuceiva for Wrinkle Treatment
The newest addition to the cosmetic neurotoxin family, also known as “Newtox” or Jeuveau in the United States. Nuceiva has recently gained Health Canada approval, marking the first new neurotoxin approved for wrinkle treatments in over two decades. Specifically developed to combat facial wrinkles, particularly on the forehead and between the eyebrows, Nuceiva positions itself as a formidable competitor to Botox with its advanced, purified botulinum toxin formulation.
Nuceiva functions similarly to other neuromodulators by inhibiting nerve signals that cause muscle contractions. This results in muscle relaxation and a reduction in wrinkles, leading to smoother and more youthful skin.
What sets it apart? While all neuromodulators in Canada, including Botox and Dysport, utilize botulinum toxin type A, Nuceiva (prabotulinum toxin-A) is manufactured by Evolus in South Korea, whereas Botox (onabotulinum toxin-A) is produced by Allergan in Ireland. The treatment process for Nuceiva is quick, typically taking about 10-15 minutes, with minimal to no downtime, similar to Botox and Dysport.
Nuceiva is distinguished by its rapid onset of action, with results visible in as little as two days, and its effects may last up to five months. This “next-generation” neurotoxin claims a more purified and precise formulation compared to its counterparts. This purity helps minimize the risk of antibody formation, which can reduce the efficacy of the treatment over time. Nuceiva shares the same molecular weight as Botox (900kDa) and is crafted with greater precision, offering more natural-looking results by allowing for better muscle movement.
Since Botox’s debut over 30 years ago, the arrival of Nuceiva has been warmly received by both medical professionals and patients, representing a significant advancement in wrinkle treatment options.

 


